Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
APRE Aprea Therapeutics, Inc. daily Stock Chart
APRE [NASD]
Aprea Therapeutics, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E23.55 EPS (ttm)1.25 Insider Own12.94% Shs Outstand21.05M Perf Week-19.62%
Market Cap648.71M Forward P/E- EPS next Y-3.02 Insider Trans-37.52% Shs Float18.32M Perf Month-4.26%
Income-34.00M PEG- EPS next Q-0.62 Inst Own87.80% Short Float5.67% Perf Quarter-12.47%
Sales- P/S- EPS this Y-64.90% Inst Trans-2.62% Short Ratio6.88 Perf Half Y-30.00%
Book/sh5.38 P/B5.47 EPS next Y-22.80% ROA- Target Price39.00 Perf Year-
Cash/sh5.56 P/C5.30 EPS next 5Y- ROE- 52W Range15.10 - 53.11 Perf YTD-35.89%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-44.61% Beta-
Dividend %- Quick Ratio10.80 Sales past 5Y- Gross Margin- 52W Low94.83% ATR2.45
Employees13 Current Ratio10.80 Sales Q/Q- Oper. Margin- RSI (14)35.18 Volatility7.08% 7.40%
OptionableNo Debt/Eq0.00 EPS Q/Q85.00% Profit Margin- Rel Volume1.28 Prev Close30.81
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume151.07K Price29.42
Recom2.20 SMA20-17.63% SMA50-10.39% SMA200-9.25% Volume192,747 Change-4.51%
Jun-22-20Initiated H.C. Wainwright Neutral $30
Apr-21-20Initiated Robert W. Baird Outperform $45
Oct-28-19Initiated RBC Capital Mkts Outperform $33
Oct-28-19Initiated Morgan Stanley Equal-Weight $23
Oct-28-19Initiated JP Morgan Neutral $23
Jul-01-20 10:32AM  
How Aprea Therapeutics (APRE) Stock Stands Out in a Strong Industry
Zacks
07:12AM  
2 Biotech Stocks That Could Soar in 2020
Motley Fool
06:30AM  
We're Hopeful That Aprea Therapeutics (NASDAQ:APRE) Will Use Its Cash Wisely
Simply Wall St.
Jun-29-20 07:00AM  
Aprea Therapeutics Appoints Fouad Namouni, M.D. and Richard Peters, M.D., Ph.D. to Board of Directors
GlobeNewswire
Jun-12-20 04:15PM  
Hedge Funds Warming Up To Aprea Therapeutics, Inc. (APRE)
Insider Monkey
06:00AM  
Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 (Eprenetapopt) and Azacitidine in Patients with TP53 Mutant Myelodysplastic Syndromes and Acute Myeloid Leukemia at the 25th European Hematology Association Annual Meeting
GlobeNewswire
Jun-11-20 10:44PM  
Aprea Therapeutics (APRE) in Focus: Stock Moves 5.8% Higher
Zacks
Jun-10-20 09:39AM  
Is Aprea Therapeutics Stock a Buy?
Motley Fool +5.75%
Jun-03-20 08:00AM  
Aprea Therapeutics Completes Full Enrollment of Phase 3 Clinical Trial in TP53 Mutant Myelodysplastic Syndromes (MDS)
GlobeNewswire
May-27-20 09:21AM  
Arcos Dorados (ARCO) in Focus: Stock Moves 10.8% Higher
Zacks
May-18-20 08:00AM  
Aprea Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare Conference
GlobeNewswire
May-15-20 07:30AM  
Aprea Therapeutics Reports First Quarter 2020 Financial Results and Provides Update on Business Operations
GlobeNewswire +5.04%
May-11-20 10:57AM  
Why Aprea Therapeutics (APRE) Stock Might be a Great Pick
Zacks +6.86%
Apr-27-20 07:00AM  
INVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Aprea Therapeutics, Inc. for Potential Breach of Fiduciary Duty Claims
GlobeNewswire
Apr-06-20 08:00AM  
Aprea Therapeutics Launches New Corporate Website - www.aprea.com
GlobeNewswire +6.45%
Apr-02-20 06:11AM  
Have Insiders Been Buying Aprea Therapeutics, Inc. (NASDAQ:APRE) Shares This Year?
Simply Wall St.
Mar-26-20 08:00AM  
Aprea Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
GlobeNewswire -11.50%
Feb-13-20 08:00AM  
Aprea Therapeutics Appoints Gregory S. Wessels as Vice President, Commercial
GlobeNewswire
Jan-30-20 07:30AM  
Aprea Therapeutics Receives FDA Breakthrough Therapy Designation for APR-246 in Combination with Azacitidine for the Treatment of Myelodysplastic Syndromes (MDS) with a TP53 Mutation
GlobeNewswire
Jan-09-20 08:00AM  
Aprea Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2020
GlobeNewswire
Jan-03-20 05:56AM  
We're Hopeful That Aprea Therapeutics (NASDAQ:APRE) Will Use Its Cash Wisely
Simply Wall St. -9.49%
Dec-17-19 10:08AM  
Agios' Tibsovo Wins FDA's Breakthrough Therapy Tag for MDS
Zacks
Dec-12-19 08:30AM  
Recap and Update of Positive Data from Phase Ib/II Clinical Trials of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Presented at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
GlobeNewswire +10.28%
Dec-09-19 11:00AM  
Aprea Therapeutics Presents Results From U.S. Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
GlobeNewswire
11:00AM  
Aprea Therapeutics Presents Results From French Phase Ib/II Clinical Trial of APR-246 and Azacitidine (AZA) in Patients with TP53 Mutant Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) at the 2019 American Society of Hematology (ASH) Annual Meeting in Orlando
GlobeNewswire
Dec-07-19 08:35AM  
The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling
Benzinga
Nov-29-19 09:24AM  
Geron (GERN) Stock Surges 40% YTD: What's Driving the Rally?
Zacks +6.92%
Nov-14-19 04:15PM  
Aprea Therapeutics Reports Third Quarter 2019 Financial Results
GlobeNewswire +10.37%
Nov-11-19 04:40PM  
RBC: 3 Stock Picks Set to Soar 30%+
TipRanks
Nov-06-19 09:15AM  
Aprea Therapeutics to Present Data from U.S. Phase 1b/2 MDS/AML Trial and French Phase 1b/2 MDS/AML Trial at 61st American Society of Hematology Annual Meeting
GlobeNewswire
Oct-11-19 05:01PM  
Gates-Backed Vir Biotechnology Flops in Trading Debut
Bloomberg
04:04PM  
Insiders Roundup: Facebook, American Defense Systems
GuruFocus.com
Oct-08-19 03:59PM  
Large Amounts Of Insider Trading In Aprea Therapeutics Following IPO
Benzinga -6.47%
Oct-07-19 04:15PM  
Aprea Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares
GlobeNewswire +6.19%
Oct-03-19 11:09AM  
Aprea Therapeutics' stock opens 3.1% above IPO price, then rises further
MarketWatch
Oct-02-19 11:03PM  
Aprea Therapeutics Announces Pricing of Initial Public Offering
GlobeNewswire
Sep-30-19 10:21AM  
IPO Outlook For The Week: Banks And Biotechs
Benzinga
Sep-23-19 08:55AM  
Aprea Therapeutics to offer 5 million shares in its IPO, priced at $14 to $16 each
MarketWatch
Aprea Therapeutics, Inc., a biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. Its lead product candidate is APR-246, a small molecule p53 reactivator that is in late-stage clinical development for hematologic malignancies, including myelodysplastic syndromes and acute myeloid leukemia. The company was founded in 2006 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
KDev Investments AB10% OwnerJul 07Sale34.55241,7038,350,8391,992,586Jul 07 05:41 PM
ROCKLAGE SCOTT MDirectorJun 16Sale33.30120,1644,001,46175,965Jun 18 07:23 PM
5AM Ventures IV, L.P.10% OwnerJun 16Sale33.30140,0004,662,00075,965Jun 18 07:22 PM
ROCKLAGE SCOTT MDirectorJun 11Sale28.75245,0007,044,41280,772Jun 15 09:13 PM
5AM Ventures IV, L.P.10% OwnerJun 11Sale28.75245,0007,044,41280,772Jun 15 09:12 PM
ROCKLAGE SCOTT MDirectorMay 19Sale35.15255,0008,963,25090,572May 21 09:32 PM
5AM Ventures IV, L.P.10% OwnerMay 19Sale35.15255,0008,963,25090,572May 21 09:31 PM
KDev Investments AB10% OwnerApr 13Sale31.25210,5486,579,6252,234,289Apr 15 09:18 AM
open in yahoo | open in reuters | open in google